Introduction
============

Hepatitis B virus (HBV) is a major cause of morbidity and mortality worldwide. The People's Republic of China has one of the world's highest rates of HBV infection despite the availability of an effective vaccine,[@b1-dddt-8-013] and consequently chronic hepatitis B (CHB) remains a significant health burden in the People's Republic of China. It is estimated that 93 million individuals in the People's Republic of China are infected with HBV,[@b1-dddt-8-013] including 20 million with active CHB.[@b2-dddt-8-013]

The aims of this review are to describe the current status of anti-HBV therapy in the People's Republic of China, with particular focus on the use of entecavir, and to summarize the data describing the cost-effectiveness of entecavir compared with other anti-HBV therapies in Chinese patients with CHB. Data emerging from studies on the use of entecavir in special population of Chinese patients, including those with cirrhosis and those undergoing liver transplantation and those on immunosuppressive therapy, are also discussed.

Current status of anti-HBV treatment in the People's Republic of China
======================================================================

In the updated 2010 Chinese CHB guidelines, two interferon (IFN)-based therapies (conventional IFN and pegylated-IFN-alpha-2a or pegylated-IFN-alpha-2b \[pegIFN-α2a or pegIFN-α2b, respectively\]) and the nucleos(t)ides lamivudine, adefovir, telbivudine, and entecavir are currently recommended for the treatment of patients with hepatitis B e-antigen (HBeAg)-positive CHB.[@b2-dddt-8-013] For patients with HBeAg-negative CHB and those with cirrhosis, nucleos(t)ide analogs with high potency and low resistance rates, such as entecavir, are preferred. The Asian-Pacific consensus statement on the management of CHB recommends that conventional IFN or pegIFN-α2a, lamivudine, adefovir, entecavir, telbivudine, and the nucleotide analog, tenofovir, can all be considered for initial therapy in patients without liver decompensation, although tenofovir has not yet been launched in the People's Republic of China.[@b3-dddt-8-013]

A recent study investigating trends in the management of CHB at a teaching hospital in South West China demonstrated that although the majority of physicians surveyed were aware of the Chinese consensus recommendations for the management of CHB, 28% would recommend conventional IFN or pegIFN, but not nucleos(t)ide therapy, as the initial treatment for patients with hepatitis B surface antigen (HBsAg)-positive disease.[@b4-dddt-8-013] Approximately 37% (44/120) of the physicians surveyed reported experience with entecavir, which was lower than the number of physicians who reported experience with lamivudine (84%; 101/120) or adefovir (57%; 68/120) nucleos(t)ide therapy, thus demonstrating a lack of awareness of guidelines, particularly on the use of entecavir. Furthermore, the proportion of patients with CHB receiving any anti-HBV treatment in the People's Republic of China is often low, despite the wide availability of therapies.[@b5-dddt-8-013] Although entecavir has been included in the government health insurance program since 2009, some patients still have to pay for their own treatment where costs exceed their annual limits, which means treatment remains unaffordable for many individuals.[@b5-dddt-8-013]

According to data released by the market research firm, IMS Health, entecavir currently accounts for 26% of the market share for HBV treatments in the People's Republic of China, compared with 39% for adefovir.[@b6-dddt-8-013] Lamivudine and telbivudine, respectively, account for 22% and 8% of the market share.

Because the cost of therapy is an issue in the People's Republic of China, particularly for entecavir, many pharmaceutical companies, including Jiangsu Chia-Tai Tianqing Pharmaceutical Co., Ltd. (Jiangsu, People's Republic of China), Jiangxi Qingfeng Pharmaceutical Co., Ltd. (Jiangxi, People's Republic of China), and Dawnrays Pharmaceutical Holdings Ltd. (Hong Kong), produce generic versions of entecavir. However, many of these generic entecavir drugs are only supported by data from bioequivalence studies, and there is a distinct lack of long-term efficacy studies. In general, generic entecavir has been shown to be effective in the management of CHB, with the advantage of low cost and high cost-effectiveness compared with Baraclude® (Bristol-Myers Squibb, New York, NY, USA).[@b7-dddt-8-013]--[@b10-dddt-8-013] However, the majority of these studies are observational, and no investigations to date have demonstrated enhanced efficacy or an improved safety profile with generic entecavir compared with Baraclude.[@b11-dddt-8-013] Therefore, although generic entecavir drugs are less expensive, their long-term efficacy and safety remains to be fully established.

Efficacy and safety of entecavir in treatment-naïve Chinese patients with CHB
=============================================================================

A number of studies have demonstrated that entecavir is an effective and well tolerated treatment for Chinese patients with CHB.[@b12-dddt-8-013],[@b13-dddt-8-013] A retrospective real-life study assessed the efficacy and safety of long-term treatment with entecavir in 230 treatment-naïve Chinese patients with CHB treated at the Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, between June 2006 and September 2012.[@b12-dddt-8-013] Reductions in HBV DNA and increased virologic responses were observed at 12 and 24 weeks. Over the treatment period, incremental increases in rates of undetectable levels of HBV DNA were observed, ie, \>90% after 2 years and up to 100% after 5 years, demonstrating that entecavir is a potent anti-HBV therapy ([Figure 1](#f1-dddt-8-013){ref-type="fig"}). In addition, entecavir was well tolerated, with no serious adverse events reported.

The efficacy of entecavir in terms of viral suppression, drug resistance, and safety have also been examined in a large cohort study of treatment-naïve patients with CHB and treated with entecavir at the Department of Medicine, Queen Mary Hospital, University of Hong Kong, between July 2005 and November 2007.[@b13-dddt-8-013] Incremental increases in rates of undetectable HBV DNA, HBeAg seroconversion, and alanine transaminase (ALT) normalization were observed, reaching 92%, 44%, and 90%, respectively, at year 3. Overall, 100% and 77% of patients with baseline HBV DNA levels \< and ≥8 log~10~ copies/mL, respectively, had undetectable HBV DNA at year 3. The cumulative rate of entecavir-resistant mutations was 1% at year 3. Three patients experienced virologic breakthrough, comprising one patient who developed resistance, one patient with subsequent HBeAg seroconversion, and another patient with a subsequent decline in HBV DNA levels. No serious adverse events were reported.

Taken together, these studies show that long-term therapy with entecavir is a highly effective anti-HBV treatment for Chinese patients, with a favorable tolerability profile. Indeed, in a retrospective study of 129 patients with CHB, although short-term treatment with entecavir rapidly suppressed HBV replication, it did not increase the short-term survival rate or prevent long-term progression to liver failure, thus supporting the use of long-term treatment strategies.[@b14-dddt-8-013]

Entecavir has also been demonstrated to be an effective and well tolerated treatment option for HBV-infected patients with schistosomiasis, one of the world's most important helminth infections in terms of global burden of morbidity and mortality, particularly in the People's Republic of China.[@b15-dddt-8-013] Patients with CHB and schistosomiasis typically suffer greater morbidity compared with those presenting with either infection alone.[@b16-dddt-8-013] In a study assessing the efficacy and safety of entecavir in patients with CHB and schistosomiasis japonica, entecavir demonstrated statistically significant improvement in fibrosis markers after 52 weeks of treatment compared with patients who received no anti-HBV therapy.[@b15-dddt-8-013] In addition, treatment with entecavir was associated with an improvement in Ishak fibrosis score. More than 80% of patients in the entecavir group achieved undetectable levels of HBV DNA, and almost 70% achieved normalization of ALT. No serious adverse events were observed throughout the treatment period.

A randomized, double-blind, double-dummy, controlled, multicenter study compared the generic entecavir drug, TianDing (entecavir maleate tablets; Jiangsu Chia-Tai Tianqing Pharmaceutical Co., Ltd.) with Baraclude in Chinese patients with HBeAg-negative CHB.[@b11-dddt-8-013] Similar efficacy and safety data were observed between the two treatment groups, with comparable decreases in mean HBV DNA levels, rates of undetectable HBV DNA at week 48, normalization of ALT, and incidence of adverse events. However, long-term studies are still required to establish the safety and efficacy of generic entecavir drugs in the People's Republic of China.

A novel estimation of the impact of entecavir on long-term mortality and morbidity rates for CHB in the People's Republic of China concluded that entecavir significantly slowed disease progression, thus reducing mortality rates.[@b17-dddt-8-013] It is important to note, however, that hepatic steatosis is significantly associated with entecavir failure, with levels of HBV DNA clearance and seroconversion being markedly lowered.[@b18-dddt-8-013]

Efficacy of entecavir compared with other HBV treatment options
===============================================================

The Chinese guidelines for the treatment of CHB recommend use of therapies with high potency and low resistance, such as entecavir, for nucleos(t)ide-naïve patients.[@b2-dddt-8-013] A review examining the evidence provided by one pharmacokinetic study and three clinical studies conducted in the People's Republic of China concluded that entecavir should be recommended as a first-line therapeutic choice among the currently available anti-HBV therapies.[@b19-dddt-8-013] Overall, entecavir was associated with a rapid reduction in serum HBV DNA levels, with a reduction of \>5 log~10~ copies/mL by week 12 and undetectable levels in 75% of cases by week 48. In addition, emergence of drug resistance in the nucleos(t)ide-naïve patients was rare, demonstrating the potential efficacious nature of long-term treatment using entecavir.[@b19-dddt-8-013] In support of this, entecavir has recently demonstrated superior antiviral efficacy compared with lamivudine, adefovir, and telbivudine.[@b20-dddt-8-013] REALM (Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated With Nucleoside/Nucleotide Monotherapy for Patients With Chronic HBV Infection) is an ongoing global, Phase IV, prospective, observational, open-label study comparing entecavir with other standard-of-care anti-HBV nucleos(t) ide therapies in patients with CHB. The People's Republic of China substudy is investigating the long-term efficacy and safety of entecavir versus other standard-of-care therapies in patients enrolled at 50 centers in a real-world setting in the People's Republic of China. Interim results for the People's Republic of China substudy were presented at the 2013 Asian Pacific Association for the Study of the Liver conference, and demonstrated that more entecavir-treated patients (n=1,724) achieved HBV DNA levels \<50 IU/mL at 24, 48, 96, 144, and 192 weeks compared with those receiving other standard-of-care treatments (lamivudine n=69; adefovir n=1,612; telbivudine n=39).[@b20-dddt-8-013] Serious treatment-related adverse events were infrequent (\<1%) and comparable between the treatment arms. Overall, these results demonstrate superior antiviral efficacy of entecavir compared with lamivudine, adefovir, and telbivudine, and support the current Asian-Pacific treatment guidelines recommendation to use entecavir as a first-line therapeutic option for patients with CHB. In addition, a number of studies in the People's Republic of China have directly compared entecavir with other nucleos(t)ide analogs that are currently recommended, including lamivudine, adefovir, and telbivudine.[@b21-dddt-8-013]--[@b29-dddt-8-013]

Entecavir versus lamivudine
===========================

Entecavir has demonstrated efficacy superior to that of lamivudine in a number of studies comparing the two therapies in Chinese patients with CHB.[@b21-dddt-8-013]--[@b24-dddt-8-013] A multicenter study evaluated the long-term efficacy of entecavir in patients who continued entecavir therapy for up to 144 weeks.[@b21-dddt-8-013] A total of 519 patients received either entecavir or lamivudine in an initial 96-week randomized, double-blind, controlled efficacy study. Entecavir resulted in a greater reduction in serum HBV DNA levels from baseline at weeks 12 and 48 and a higher rate of undetectable HBV DNA compared with lamivudine. The authors concluded that entecavir was superior to lamivudine in achieving virologic and biological responses in Chinese patients with CHB.

A randomized, double-blind, controlled study assessed the safety and efficacy of entecavir versus lamivudine in HBeAg-positive, treatment-naïve patients from Jilin Province, the People's Republic of China.[@b23-dddt-8-013] Rates of viral suppression at weeks 24 and 48 were significantly higher with entecavir than with lamivudine. The mean reduction in serum HBV DNA levels was also significantly greater in entecavir-treated patients. The safety profile was comparable between the two therapies.

Another study assessed the long-term efficacy and safety of entecavir and lamivudine in 519 nucleos(t)ide-naïve adults with CHB from 26 sites across the People's Republic of China over a follow-up period of 3 years.[@b22-dddt-8-013] The mean reduction in HBV DNA levels at week 12 was significantly greater for the entecavir-treated group than for the lamivudine-treated group (−5.07 log~10~ copies/mL versus −4.53 log~10~ copies/mL; *P*\<0.001). Of 160 patients who received entecavir continuously for 144 weeks, 89% had undetectable serum HBV DNA levels, 86% showed normalization of ALT, 20% had loss of HBeAg, 8% experienced HBeAg seroconversion, and 3% showed evidence of genotypic mutation.

Taken together, these studies demonstrate superior efficacy for entecavir compared with lamivudine in Chinese patients with CHB. However, in an earlier study comparing entecavir and lamivudine, entecavir demonstrated similar virologic, biochemical, and serologic outcomes in nucleos(t)ide-naïve Chinese patients with CHB.[@b24-dddt-8-013] Although a higher proportion of patients treated with entecavir achieved HBV DNA \<300 copies/mL (79% versus 46%; *P*\<0.0001), similar proportions of entecavir-treated and lamivudine-treated patients achieved confirmed ALT normalization and HBeAg seroconversion, and the safety profile was similar between the groups.

Entecavir versus adefovir
=========================

To date, only one study has compared the efficacy of entecavir with that of adefovir in Chinese patients with CHB. This was a prospective study by Chen et al comparing the efficacy of adefovir with that of entecavir over a 2-year period in 100 treatment-naïve patients.[@b25-dddt-8-013] The authors concluded that entecavir was significantly superior to adefovir, with entecavir therapy being associated with a greater mean reduction in HBV DNA levels compared with adefovir at 24 months (−7.5 log~10~ copies/mL versus −6.3 log~10~ copies/mL, respectively; *P*=0.003). Both treatments demonstrated similar rates of ALT normalization, HBeAg seroconversion, and overall adverse events, and there were no instances of entecavir-associated or adefovir-associated mutations.

Entecavir versus lamivudine plus adefovir
=========================================

A comparison of the efficacy of entecavir versus that of lamivudine and adefovir combination therapy in a prospective case-control study of Chinese patients with CHB demonstrated that both treatment strategies were equally effective in reducing HBV DNA levels in treatment-naïve patients.[@b26-dddt-8-013] No statistically significant differences in mean reduction of HBV DNA levels or in rates of undetectable HBV DNA were observed between the two treatment groups over 48 weeks. The adverse event profiles for the two treatments were also comparable. However, another study demonstrated that entecavir had superior antiviral efficacy compared with combination therapy using lamivudine and adefovir.[@b27-dddt-8-013] Fifty patients with HBeAg-positive CHB were treated with entecavir or lamivudine plus adefovir over a treatment period of 96 weeks. Complete virologic response rates were significantly greater in the entecavir group compared with the lamivudine-adefovir combination therapy group (86% versus 43%; *P*=0.003). Patients in both treatment groups demonstrated significant improvement in biochemical liver responses, and there were no cases of virologic breakthrough. Further, no treatment-related adverse events were reported throughout the treatment and follow-up periods.

Entecavir versus telbivudine
============================

Entecavir has also demonstrated efficacy comparable with that of telbivudine.[@b28-dddt-8-013] In a study of ethnic Han Chinese patients with previously untreated HBeAg-positive CHB, similar mean reductions in serum levels of HBV DNA at weeks 12 and 24 were observed with the two treatments, as well as similar proportions of patients achieving undetectable HBV DNA. Both treatments demonstrated comparable tolerability profiles. However, in a retrospective single-center study in patients from Taiwan, entecavir was associated with better clinical outcomes than was telbivudine.[@b29-dddt-8-013] Rates of ALT normalization (85% versus 78%; *P*\<0.048) and undetectable HBV DNA (96% versus 75%; *P*\<0.001) were significantly higher for entecavir than for telbivudine, and the incidence of viral resistance (1% versus 22%; *P*\<0.001) was significantly lower in the entecavir-treated group. HBeAg seroconversion and the cumulative incidence of hepatocellular carcinoma were comparable between the two treatment groups.

Taken together, these studies demonstrate that entecavir has a tolerability profile similar to that of the other nucleos(t) ides, including adefovir and lamivudine, but is associated with superior antiviral efficacy in Chinese patients with CHB ([Table 1](#t1-dddt-8-013){ref-type="table"}).

Cost-effectiveness of entecavir
===============================

The cost of treatment plays an important role in the decision-making process when treating patients with CHB in the People's Republic of China because some patients are required to pay for their treatment. Although entecavir is widely available in the People's Republic of China, it is viewed as a more expensive treatment option compared with other nucleos(t)ide therapies.[@b17-dddt-8-013] However, several studies have compared the overall cost-effectiveness of entecavir with that of other therapies and demonstrated that entecavir is a more cost-effective option.[@b17-dddt-8-013],[@b30-dddt-8-013],[@b31-dddt-8-013] Wei et al used a Markov transition model of disease states based on available natural history data to simulate CHB.[@b17-dddt-8-013] Over a treatment duration of 5 years, entecavir was estimated to result in a cost-saving of US\$2.69 per day when compared with no treatment. In addition, long-term entecavir resulted in daily cost-savings of US\$2.33 and US\$1.73 at 1 year and 2 years, respectively, when compared with short-term use. Compared with other HBV therapies, entecavir offered daily cost-savings of US\$0.90--1.81. It was concluded that long-term therapy with entecavir is a favorable therapeutic and cost-effective strategy. In another study, a Markov analysis was conducted to examine the cost-effectiveness of nucleos(t)ide analog therapy for HBV in the People's Republic of China.[@b30-dddt-8-013] In an HBeAg-positive cohort, treatment with entecavir was associated with a gain of 11.8 quality-adjusted life years, a 24% incidence of cirrhosis, a 15% incidence of hepatocellular carcinoma, and a 23% incidence of death. This study demonstrated that entecavir was the most cost-effective treatment option when compared with lamivudine and adefovir, and achieved the best health outcomes overall compared with other treatment options in the People's Republic of China.

In another economic analysis comparing entecavir and lamivudine for the treatment of CHB in Hong Kong, entecavir was expected to reduce the incidence of compensated cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma by 42%, 57%, and 49%, respectively.[@b31-dddt-8-013] Although the overall disease management cost for entecavir was 68% higher than that predicted for lamivudine for a treatment period of 2 years, this was reduced to 17% after projecting the 2-year treatment duration to 10 years. The incremental cost per quality-adjusted life year gained for entecavir compared with lamivudine was \$US13,759. As such, entecavir was considered to be cost-effective compared with lamivudine in treatment-naïve patients with CHB in Hong Kong, when long-term medical consequences were taken into consideration.

These studies demonstrate that although entecavir is associated with higher costs at the start of treatment, long-term therapy offers economic benefits for the treatment of CHB in Chinese patients when compared with other available nucleos(t)ide therapies.

Entecavir in Chinese patients with drug-resistant CHB
=====================================================

Lamivudine is associated with a high rate of viral resistance,[@b32-dddt-8-013]--[@b35-dddt-8-013] and continued lamivudine treatment in lamivudine-resistant patients can result in increased viral load, hepatic flares that may lead to decompensation, or reversal of histologic improvement. In contrast, entecavir has a greater barrier to resistance in Chinese patients with CHB compared with lamivudine and adefovir.[@b36-dddt-8-013] Thus, as well as having superior antiviral efficacy, entecavir is also associated with less resistance compared with other nucleos(t)ide therapies in Chinese patients with CHB.

Entecavir in lamivudine-resistant CHB
-------------------------------------

Although entecavir monotherapy has been shown to induce a marked reduction in HBV DNA levels in patients with lamivudine-refractory CHB,[@b37-dddt-8-013] sequential use of nucleos(t)ide monotherapies is associated with multidrug resistance, so add-on therapy may be a more effective therapeutic strategy in these patients. Indeed, a retrospective study concluded that while neither entecavir nor adefovir are optimal as monotherapies, switching to adefovir or entecavir combination therapy may be the most effective treatment regimen in lamivudine-resistant patients with CHB.[@b38-dddt-8-013] The benefits of combination therapy using entecavir and adefovir were further demonstrated in a study conducted in 91 adult patients with lamivudine-resistant CHB ([Table 2A](#t2-dddt-8-013){ref-type="table"}).[@b39-dddt-8-013] This was a comparative study of adefovir monotherapy (n=29), adefovir add-on to lamivudine (n=30), and adefovir-entecavir combination therapy (n=32). The most significant decrease in HBV DNA levels from baseline was observed in patients receiving entecavir in combination with adefovir (−5.58 log~10~ IU/mL at 24 months; *P*\<0.01 versus other treatment groups). No incidences of viral breakthrough or genotypic resistance were observed in the combination-therapy group after 24 months (*P*\<0.05 versus other treatment groups). Overall, the combination of entecavir and adefovir demonstrated faster and significantly greater suppression of HBV DNA levels compared with adefovir add-on to lamivudine. Therefore, as well as having a lower barrier to resistance as a monotherapy, entecavir can also be used as part of a combination therapy in patients refractory to lamivudine.

Entecavir in adefovir-resistant CHB
-----------------------------------

Adefovir-resistant mutations are also increasingly recognized. A number of studies have assessed the use of entecavir in adefovir-refractory Chinese patients with CHB ([Table 2B](#t2-dddt-8-013){ref-type="table"}). A prospective, controlled study compared the safety and efficacy of entecavir with adefovir in combination with telbivudine in patients with CHB who were resistant to adefovir.[@b40-dddt-8-013] After 48 weeks of treatment, there were no statistically significant differences in rates of virologic response between the two treatment groups (*P*=0.195). HBeAg loss was experienced by 33% of patients treated with combination therapy, compared with 11% of patients who received entecavir, and a similar rate of ALT normalization at week 48 was seen for both groups (85% for telbivudine and adefovir versus 71% for entecavir; *P*=0.428) Virologic breakthrough occurred in two entecavir-treated patients and one patient who received telbivudine plus adefovir, with no significant differences between the two groups at week 48. Thus, entecavir demonstrated effective antiviral efficacy in patients who were resistant to adefovir. Another prospective, controlled study comparing entecavir monotherapy with lamivudine plus adefovir in adefovir-refractory Chinese patients with CHB also demonstrated favorable results with the use of entecavir.[@b41-dddt-8-013] Biochemical response rates were 97% and 84% (*P*=0.097), and virologic response rates were 97% and 68% (*P*=0.003) in the lamivudine plus adefovir and entecavir monotherapy groups, respectively, demonstrating that single-agent entecavir is also an effective therapeutic strategy in adefovir-resistant Chinese patients with CHB.

Entecavir in multidrug-resistant CHB
------------------------------------

The superiority of add-on therapy has only recently been established, thus many patients with CHB have received sequential monotherapy regimens that have resulted in resistance to multiple therapies. Entecavir combination therapy may also be effective in these patients. The use of entecavir in combination with adefovir has been investigated in 52 Chinese patients with CHB who had failed two or more previous nucleos(t)ide therapies.[@b42-dddt-8-013] No patient treated with entecavir and adefovir combination therapy developed primary non-response or viral breakthrough during follow-up. In addition, all patients achieved ALT normalization, and the rate of HBeAg/anti-HBe seroconversion was 16% (7/45 patients) at 12 months, and 27% (12/45 patients) at 24 months of treatment. No treatment-related adverse events were reported throughout the treatment period. Thus, entecavir in combination with adefovir can be considered an effective therapeutic regimen in patients with multiple nucleos(t)ide therapy failures.

Entecavir has also been evaluated as both monotherapy and in combination with adefovir in Chinese patients with lamivudine-resistant CHB who have also failed prior lamivudine plus adefovir therapy.[@b43-dddt-8-013] After 24 weeks of treatment, a significantly lower rate of HBV DNA levels \<500 copies/mL was seen in entecavir-treated patients than in those who received entecavir plus adefovir (29% versus 81%; *P*=0.004). By week 48, all patients in the entecavir-adefovir combination therapy group had achieved HBV DNA levels \<500 copies/mL. ALT normalization was achieved by 43% and 92% of the entecavir and entecavir-adefovir combination therapy groups, respectively, at week 24, and by 57% and 100%, respectively, at week 48. Taken together, these studies demonstrate that the use of entecavir in combination with adefovir is associated with favorable antiviral efficacy in patients with multidrug-resistant CHB.

Benefits of entecavir in Chinese patients with HBV-related conditions
=====================================================================

Reduced risk of hepatic events
------------------------------

HBV infection has consistently been demonstrated to be an independent risk factor for development of cirrhosis and hepatocellular carcinoma.[@b44-dddt-8-013] As such, the main goal of therapy for CHB is to prevent the development of long-term complications of HBV infection, including cirrhosis and hepatocellular carcinoma.[@b3-dddt-8-013]

A retrospective cohort study from Hong Kong examined the efficacy of entecavir with regard to clinical outcomes and death rates, with the primary outcome of a 5-year cumulative probability of hepatic events, defined as any cirrhotic complication, hepatocellular carcinoma, or liver-related mortality.[@b44-dddt-8-013] In 482 patients with cirrhosis who received entecavir therapy, there was a reduced risk of all clinical outcomes compared with a cohort of treatment-naïve patients with cirrhosis. However, in entecavir-treated patients who failed to achieve undetectable HBV DNA levels, the risk of developing a hepatic complication was comparable with that in untreated patients. The authors concluded that entecavir reduces the risk of hepatic events, particularly among individuals with maintained viral suppression.

The beneficial effects of a virologic response to entecavir in preventing progression of liver disease in patients with and without cirrhosis have also been observed in a study from Taiwan.[@b45-dddt-8-013] Further, a virologic response to entecavir reduced the risk of clinical events and hepatocellular carcinoma in nucleos(t)ide-experienced patients with prior lamivudine-resistant or adefovir-resistant mutants, but not in nucleos(t)ide-naïve patients or nucleos(t)ide-experienced patients who had never developed lamivudine-resistant or adefovir-resistant mutants.

A real-world study in Taiwan investigated the safety and efficacy of entecavir in treatment-naïve, HBeAg-positive patients with compensated liver disease.[@b46-dddt-8-013] Long-term entecavir therapy was associated with favorable biochemical and virologic responses, but only modest serologic responses. Baseline ALT levels more than five times the upper limit of normal and lower baseline HBV DNA levels were also demonstrated to be favorable predictors of serologic response.

Efficacy in patients with decompensated cirrhosis
-------------------------------------------------

More recently, a growing body of data has demonstrated that entecavir is associated with favorable safety and efficacy in CHB patients with decompensated cirrhosis.[@b47-dddt-8-013] Liaw et al reported that entecavir 1 mg/day was associated with superior antiviral efficacy at week 48 compared with adefovir 10 mg/day (the proportion of patients achieving HBV DNA \<300 copies/mL was 57% versus 20% respectively; *P*\<0.0001) in patients with CHB who had hepatic decompensation (Child-Turcotte-Pugh score ≥7).[@b48-dddt-8-013] Approximately two thirds of patients in both treatment groups showed stabilization or improvement in Child-Turcotte-Pugh scores. The model for end-stage liver disease score at week 48 was also improved in both treatment groups; the score for entecavir was 22.6 (baseline 17.1) and for adefovir was 21.7 (baseline 15.3). Adverse event rates were comparable between the groups, and cumulative hepatocellular carcinoma rates were 12% for entecavir patients and 20% in patients treated with adefovir. In another study, reported by Liaw et al, entecavir was well tolerated in patients with decompensated liver disease, with an overall improvement in virologic, biochemical, and clinical parameters being demonstrated.[@b49-dddt-8-013] However, long-term studies in Chinese patients with CHB-associated decompensated cirrhosis are required to confirm these findings.

Efficacy in patients with HBV-associated liver failure
------------------------------------------------------

CHB is the most common cause of liver failure, and can develop as acute liver failure, acute-on-chronic liver failure, or chronic decompensation of end-stage liver disease. Although the US guidelines for diagnosis and treatment of CHB recommend entecavir as a first-line antiviral drug for patients with HBV-related liver failure,[@b50-dddt-8-013] data are lacking to support the use of entecavir in Chinese patients.

A recent meta-analysis demonstrated that nucleos(t)ide analog therapy, including entecavir, was associated with improved survival, significant reductions in serum HBV DNA levels at 3 months, and significantly higher rates of HBeAg seroconversion.[@b51-dddt-8-013] These findings are in agreement with those of Cui et al, who observed that although entecavir or lamivudine did not significantly increase 3-month survival rates in patients with HBV-associated acute-on-chronic liver failure compared with patients who received no therapy, treatment with either nucleos(t)ide analog was associated with significantly lower levels of HBV DNA and lower rates of recurrence of acute-on-chronic liver failure.[@b52-dddt-8-013] Further, timely administration of entecavir has been associated with an improved prognosis in patients with HBeAg-negative acute-on-chronic liver failure.[@b53-dddt-8-013] Further research is required to assess the therapeutic use of entecavir in Chinese patients with liver failure attributed to CHB infection.

Benefits of entecavir treatment after liver transplantation
===========================================================

Prevention of recurrence of HBV
-------------------------------

Liver transplantation is the only treatment strategy available for HBV-related end-stage liver disease.[@b54-dddt-8-013] However, HBV recurrence is a frequent complication, occurring in up to 12% of patients.[@b54-dddt-8-013] Although the use of hepatitis B immunoglobulin plus lamivudine has reduced the HBV recurrence rate, long-term use of lamivudine is associated with a high rate of resistance in HBV, as are other nucleotide analogs, such as adefovir and telbivudine. Entecavir is associated with a lower barrier to resistance, so may be an effective strategy in preventing HBV recurrence in patients undergoing liver transplantation.

A number of studies have demonstrated that entecavir alone or in combination with HBV immunoglobulin can prevent recurrence of HBV after liver transplantation. In one small-scale study, the combination of entecavir with low-dose HBV immunoglobulin was shown to be an effective and well tolerated strategy for preventing HBV recurrence after liver transplantation.[@b54-dddt-8-013] A retrospective case-controlled study, which enrolled 252 patients between 2005 and 2007, evaluated the effects of entecavir plus lamivudine in preventing HBV recurrence after orthotopic liver allograft in Chinese patients with HBV-related end-stage liver disease.[@b55-dddt-8-013] A total of 18 patients who received lamivudine developed HBV reinfection, with an HBV reinfection rate of 10%. In contrast, no patients in the entecavir group experienced reinfection. The difference in reinfection rates between the two treatment groups was statistically significant (*P*\<0.01), as was the difference in cumulative reinfection rate (*P*\<0.01).

These findings were confirmed by Fung et al who examined the efficacy of entecavir monotherapy in suppressing HBV in Chinese patients with HBV who underwent liver transplantation.[@b56-dddt-8-013] At the time of transplantation, 26% of patients had complete viral suppression. The cumulative rate of HBsAg loss was 86% and 91% after 1 and 2 years of entecavir treatment, respectively. This study demonstrated that an HBV immunoglobulin-free regimen of entecavir monotherapy is effective for suppressing HBV in individuals undergoing liver transplantation.

A study in patients undergoing liver transplantation in Hong Kong also investigated the use of lamivudine, entecavir, or lamivudine-entecavir combination therapy.[@b57-dddt-8-013] The rates of undetectable HBV DNA at 1, 3, 5, and 8 years were 94%, 96%, 96%, and 98%, respectively, using oral antiviral therapy alone. This study demonstrated that oral nucleos(t)ide prophylaxis without HBV immunoglobulin is associated with excellent long-term survival in patients with CHB after liver transplantation. For those without pre-existing drug-resistant mutations, using an antiviral agent with a high barrier to resistance, such as entecavir, is recommended. Combination therapy is recommended for those with pre-existing drug-resistant mutations.

Treatment of immunosuppressed individuals
-----------------------------------------

Patients with active HBV infection and those who have previously been infected with HBV but have apparently cleared the virus (HBsAg-negative, but with antibodies against hepatitis B core or surface antigen) and undergo immunosuppressive therapy are at risk of HBV reactivation.[@b58-dddt-8-013] Reactivation is associated with a number of poor clinical outcomes, including elevation of serum HBV DNA and/or serum transaminase levels, jaundice, fulminant hepatic failure, and liver-related death.[@b59-dddt-8-013] Use of anti-HBV therapies during immunosuppressive therapy can prevent HBV reactivation. A recent study compared the efficacy of entecavir with that of lamivudine for preventing HBV reactivation in patients with lymphoma who were receiving chemotherapy.[@b60-dddt-8-013] The entecavir-treated group had significantly lower rates of hepatitis (6% versus 27%; *P*=0.007), HBV reactivation (0% versus 12%; *P*=0.024), and disruption of chemotherapy (6% versus 20%; *P*=0.042), demonstrating that entecavir is more effective than lamivudine in the prevention of HBV reactivation in patients receiving chemotherapy.

Summary
=======

Overall, entecavir has demonstrated effective antiviral suppression and good tolerability in Chinese patients with CHB. In this patient population, entecavir has shown antiviral efficacy comparable with that of other recommended nucleos(t)ide therapies, including lamivudine and adefovir, with a number of studies demonstrating superior efficacy with entecavir. It has also shown efficacy in lamivudine-resistant patients, either alone or in combination with other nucleos(t)ides. Entecavir reduces the risk of hepatic events in Chinese patients with CHB, and has demonstrated efficacy in those with HBV-associated decompensated cirrhosis and liver failure. In addition, entecavir can prevent HBV reactivation in patients undergoing immunosuppressive therapy.

Challenges and strategies with use of entecavir in the People's Republic of China
=================================================================================

Despite its demonstrable efficacy, a number of challenges remain regarding entecavir therapy in the People's Republic of China. None of the currently available therapies for CHB, including entecavir, induce HBsAg loss or seroconversion in the majority of patients who receive treatment. Strategies required to overcome this challenge include the exploration of combination treatment using entecavir and pegIFN-α[@b61-dddt-8-013] or the use of therapeutic vaccines.[@b62-dddt-8-013] In addition, because HBV infection cannot be cured, there is a high rate of HBV reactivation. In patients who experience recurrence, therapy cannot be stopped, and it is important to restore immune responses in patients in whom reactivation occurs. Therefore, the addition of IFN therapy may be an important consideration, although further research is needed to confirm this.

Another major challenge is that physicians in the People's Republic of China, particularly those in gastroenterology, geriatrics, and other hospital departments, demonstrate a lack of awareness of CHB guidelines, especially those working in hospitals not affiliated with a university.[@b4-dddt-8-013] This may result in patients not receiving the currently recommended first-line anti-HBV therapies, which may lead to a poorer prognosis for some. Improved education concerning the management of HBV infection is required, particularly for physicians based in county hospitals or clinics.

Medical insurance and payment capability regarding CHB treatment is also a challenge for Chinese patients with CHB. Although there is a short-term study demonstrating similar efficacy between entecavir (Baraclude) and less expensive, generic entecavir,[@b11-dddt-8-013] there is a lack of long-term evidence regarding generic entecavir drugs, so long-term follow-up studies are needed to support their use. In addition, policymakers need to objectively evaluate the optimization of treatment regimens by considering the findings of pharmacoeconomic studies that have recently demonstrated the cost-effective nature of entecavir compared with other nucleos(t)ide therapies.

Studies in the People's Republic of China have shown that entecavir has an efficacy profile in Chinese patients with CHB comparable with that observed in other ethnic patient populations. However, further research is needed to assess the use of entecavir combinations in the treatment of lamivudine-resistant disease, and in increasing HBsAg seroconversion rates in different patient populations. Improved education on the use of entecavir, particularly regarding its long-term effectiveness, is also required to ensure that both patients and physicians are aware of the clinical use of this anti-HBV therapy.
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![Effect of long-term ETV therapy on the proportion of patients with (**A**) undetectable HBV DNA and (**B**) ALT normalization.\
**Notes:** Graph created using data taken from Luo et al, 2013[@b12-dddt-8-013] and Yuen et al, 2011.[@b13-dddt-8-013] Data cannot be directly compared due to differences in experimental procedures between studies.\
**Abbreviations:** ALT, alanine transaminase; DNA, deoxyribonucleic acid; HBV, hepatitis B virus; ETV, entecavir.](dddt-8-013Fig1){#f1-dddt-8-013}

###### 

Summary of ETV efficacy versus other nucleos(t)ide therapies in Chinese patients with CHB[a](#tfn2-dddt-8-013){ref-type="table-fn"}

  Author                                                                                                                        HBV DNA \<300 copies/mL/undetectable HBV DNA   ALT normalization (≤1× ULN)                    HBeAg loss      HBeAg seroconversion                                             
  ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------------- ---------------------- --------------- --------- --------------- ----
  Yao et al[@b21-dddt-8-013],[b](#tfn3-dddt-8-013){ref-type="table-fn"}                                                         79                                             46                                             96              92                     27              27        21              23
  Yao et al[@b24-dddt-8-013],[b](#tfn3-dddt-8-013){ref-type="table-fn"}                                                         74                                             41                                             96              82                     18              25        11              19
  Yao et al[@b19-dddt-8-013],[@b22-dddt-8-013],[@b37-dddt-8-013],[c](#tfn4-dddt-8-013){ref-type="table-fn"}                     76                                             43                                             90              78                     18              20        15              18
  Ren et al[@b23-dddt-8-013],[c](#tfn4-dddt-8-013){ref-type="table-fn"}                                                         52[d](#tfn5-dddt-8-013){ref-type="table-fn"}   36[d](#tfn5-dddt-8-013){ref-type="table-fn"}   86              76                     NR              NR        15              18
  **ETV**                                                                                                                       **ADV**                                        **ETV**                                        **ADV**         **ETV**                **ADV**         **ETV**   **ADV**         
                                                                                                                                                                                                                                                                                                               
  Chen et al[@b8-dddt-8-013],[@b25-dddt-8-013],[@b26-dddt-8-013],[@b58-dddt-8-013],[e](#tfn6-dddt-8-013){ref-type="table-fn"}   84                                             55                                             97              88                     NR              NR        25              24
  **ETV**                                                                                                                       **LVD + ADV**                                  **ETV**                                        **LVD + ADV**   **ETV**                **LVD + ADV**   **ETV**   **LVD + ADV**   
                                                                                                                                                                                                                                                                                                               
  Wang et al[@b8-dddt-8-013],[@b26-dddt-8-013],[@b36-dddt-8-013],[c](#tfn4-dddt-8-013){ref-type="table-fn"}                     78[d](#tfn5-dddt-8-013){ref-type="table-fn"}   81[d](#tfn5-dddt-8-013){ref-type="table-fn"}   90              94                     0               0         0               0
  **ETV**                                                                                                                       **LdT**                                        **ETV**                                        **LdT**         **ETV**                **LdT**         **ETV**   **LdT**         
                                                                                                                                                                                                                                                                                                               
  Tsai et al[@b29-dddt-8-013],[e](#tfn6-dddt-8-013){ref-type="table-fn"}                                                        97[d](#tfn5-dddt-8-013){ref-type="table-fn"}   75[d](#tfn5-dddt-8-013){ref-type="table-fn"}   85              78                     NR              NR        43              46
  Zheng et al[@b28-dddt-8-013],[f](#tfn7-dddt-8-013){ref-type="table-fn"}                                                       58[d](#tfn5-dddt-8-013){ref-type="table-fn"}   68[d](#tfn5-dddt-8-013){ref-type="table-fn"}   74              79                     29              37        14              25

**Notes:** All data are shown as percentage of patients, unless otherwise stated.

Direct comparisons cannot be made between studies due to differences in treatment periods

96 weeks of treatment

48 weeks of treatment

data relate to undetectable HBV DNA

24 months of treatment

24 weeks of treatment.

**Abbreviations:** ALT, alanine transaminase; CHB, chronic hepatitis B; DNA, deoxyribonucleic acid; HBeAg, hepatitis B e-antigen; HBV, hepatitis B virus; ULN, upper limit of normal; ETV, entecavir; LdT, tenofovir; LVD, lamivudine; ADV, adefovir.

###### 

Summary of ETV efficacy either alone or in combination versus other nucleos(t)ide therapies in Chinese patients with drug-resistant CHB[a](#tfn10-dddt-8-013){ref-type="table-fn"}

                                                                     ADV monotherapy   ADV add-on to LVD       ADV + ETV   ETV monotherapy
  ------------------------------------------------------------------ ----------------- ----------------------- ----------- ---------------------
  **(A) LVD-resistant CHB**                                                                                                
  Ha et al[@b39-dddt-8-013]                                                                                                
   HBV DNA undetectable[b](#tfn11-dddt-8-013){ref-type="table-fn"}   49                77                      88          NA
   ALT normalization[c](#tfn12-dddt-8-013){ref-type="table-fn"}      72                80                      88          NA
   HBeAg loss[b](#tfn11-dddt-8-013){ref-type="table-fn"}             35                50                      53          NA
   HBeAg seroconversion[b](#tfn11-dddt-8-013){ref-type="table-fn"}   21                30                      38          NA
  Zhao et al[@b38-dddt-8-013]                                                                                              
   ALT normalization[c](#tfn12-dddt-8-013){ref-type="table-fn"}      75                84                      100         93
                                                                                       **LdT add-on to ADV**               **ETV monotherapy**
                                                                                                                           
  **(B) ADV-resistant CHB**                                                                                                
  Lu et al[@b40-dddt-8-013]                                                                                                
   HBV DNA undetectable[d](#tfn13-dddt-8-013){ref-type="table-fn"}                     73                                  57
   ALT normalization[d](#tfn13-dddt-8-013){ref-type="table-fn"}                        85                                  71
   HBeAg loss[d](#tfn13-dddt-8-013){ref-type="table-fn"}                               33                                  11
   HBeAg seroconversion[d](#tfn13-dddt-8-013){ref-type="table-fn"}                     20                                  0
                                                                                       **LVD add-on to ADV**               **ETV monotherapy**
                                                                                                                           
  Wang et al[@b41-dddt-8-013]                                                                                              
   HBV DNA undetectable[c](#tfn12-dddt-8-013){ref-type="table-fn"}                     97                                  68
   ALT normalization[c](#tfn12-dddt-8-013){ref-type="table-fn"}                        97                                  84
   HBeAg loss[c](#tfn12-dddt-8-013){ref-type="table-fn"}                               47                                  8
   HBeAg seroconversion[c](#tfn12-dddt-8-013){ref-type="table-fn"}                     37                                  4

**Notes:** All data are presented as percentage of patients, unless stated otherwise.

Direct comparisons cannot be made between studies due to differences in treatment periods and different experimental procedures between studies

24 months of treatment

12 months of treatment

48 weeks of treatment.

**Abbreviations:** ADV, adefovir; ALT, alanine transaminase; CHB, chronic hepatitis B; DNA, deoxyribonucleic acid; HBeAg, Hepatitis B e-antigen; HBV, hepatitis B virus; ETV, entecavir; LdT, tenofovir; LVD, lamivudine; NA, not applicable.
